The global stem cells market was valued at US$ 5,231.7 Mn in 2016, and is expected to reach US$ 13,731.5 Mn by 2025 expanding at a CAGR of 10.50% from 2017 to 2025. At the same time, the growth rate in research papers and clinical trial proposals is exponential and seemingly unstoppable. To date, only Cynata has the capablility of providing a demonstrably safe scaleable product for use in medicinal grade therapies.
With or without any doubts about the BOD, there is only one direction for this stock and that is skywards. Hold tight and keep the faith. Regards to all here.
Ann: Cynata GvHD Trial Meets all Safety & Efficacy Endpoints, page-32
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.015(6.38%) |
Mkt cap ! $45.16M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 28.0¢ | 24.5¢ | $103.8K | 408.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 35587 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 7013 | 2 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |